Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

PNC-27 Dosage Protocol | PeptideDosages.com

PNC-27 (30 mg Vial) Dosage Protocol PNC-27 (30 mg Vial) Dosage Protocol PNC-27 Dosage Chart PNC-27 is dosed at 100 mcg–500 mcg daily via subcutaneous injection in educational protocols. A 30 mg vial reconstituted with bacteriostatic water yields about 10 mg/mL

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

PNC-27 (30 mg Vial) Dosage Protocol

PNC-27 (30 mg Vial) Dosage Protocol

PNC-27 Dosage Chart

PNC-27 is dosed at 100 mcg–500 mcg daily via subcutaneous injection in educational protocols. A 30 mg vial reconstituted with bacteriostatic water yields about 10 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → 10 mg/mL concentration.

Typical daily range: 100–500 mcg once daily (gradual titration).

Easy measuring: At 10 mg/mL, 1 unit = 0.01 mL = 100 mcg on a U‑100 insulin syringe.

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

PNC-27 is a synthetic 32‑amino‑acid peptide containing an HDM‑2‑binding domain linked to a membrane‑penetrating sequence, studied preclinically for its selective cytotoxicity toward cancer cells expressing abnormal p53/HDM‑2 complexes[1][2]. No human clinical trials exist, and the FDA explicitly warns that PNC-27 products are unapproved and lack established safety data[3]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read PNC-27 Peptide: Benefits, Uses, Side Effects, Dosage, and Research.

Standard / Gradual Approach (3 mL = 10 mg/mL)

Weeks 1–2

100 mcg (0.10 mg)

1 unit (0.01 mL)

Weeks 3–4

200 mcg (0.20 mg)

2 units (0.02 mL)

Weeks 5–8

300 mcg (0.30 mg)

3 units (0.03 mL)

Weeks 9–12

400 mcg (0.40 mg)

4 units (0.04 mL)

Weeks 13–16

500 mcg (0.50 mg)

5 units (0.05 mL)

Frequency: Inject once daily subcutaneously. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.

Critical Note: No authoritative human dosing exists for PNC-27. The FDA warns that PNC-27 safety has not been established[3]. Any dosing above a few hundred micrograms per day is purely speculative[4].

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid foaming.

Gently swirl/roll until dissolved (do not shake).

Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

Peptide Vials (PNC-27, 30 mg each):

8 weeks ≈ 1 vial (~15–20 mg total used)

12 weeks ≈ 1 vial (~25 mg total used)

16 weeks ≈ 2 vials (~35–40 mg total used)

Insulin Syringes (U‑100 or 30/50‑unit for precision):

Per week: 7 syringes (1/day)

8 weeks: 56 syringes

12 weeks: 84 syringes

16 weeks: 112 syringes

Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.

8 weeks (1 vial): 3 mL → 1 × 10 mL bottle

12 weeks (1 vial): 3 mL → 1 × 10 mL bottle

16 weeks (2 vials): 6 mL → 1 × 10 mL bottle

Alcohol Swabs: One for the vial stopper + one for the injection site each day.

Per week: 14 swabs (2/day)

8 weeks: 112 swabs → recommend 2 × 100‑count boxes

12 weeks: 168 swabs → recommend 2 × 100‑count boxes

16 weeks: 224 swabs → recommend 3 × 100‑count boxes

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Frequently Asked Questions About PNC-27

Straight answers on reconstitution, dosing, and safety, everything you need to research with confidence. For research reference only.

Source: peptidemind.com ↗
02Retinalamin — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Retinalamin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
03AHK-Cu — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 50 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 50 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. AHK-Cu is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
04Teduglutide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Teduglutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
05Pemvidutide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Pemvidutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
Research context

Read sources and limitations before applying a claim.

What We Still Do Not Know: The Real Evidence Gaps

An honest inventory of open questions is more useful than a list of hopeful claims, so here is where the actual gaps lie — the places where a researcher can say precisely what is missing. The overarching problem is that Sermorelin’s own high-quality clinical evidence base is concentrated in the pediatric-diagnostic and pediatric-deficiency setting for which it was approved, and much of the modern enthusiasm rests on extrapolation from that setting, from adjacent stabilized analogs, or from mechanism alone.3 The table below separates what is reasonably established from what remains hypothesis. Pituitary stimulation Sermorelin reliably provokes endogenous GH release via GHRHR3 Durability and clinical meaning of chronic stimulation in non-deficient adults Diagnosis of GHD Validated as a provocative test (incl. GHRH-arginine)9 Whether/how to restore standardized GHRH-based testing to practice7 Somatopause / aging GH/IGF-1 decline with age is real and measurable8 Whether restoring the axis helps or harms over years8 Cognition A GHRH analog (tesamorelin) improved executive function in a trial5 Whether Sermorelin specifically reproduces this effect5 Body composition Stabilized GHRH analog reduces visceral fat in a defined disease10 Whether Sermorelin changes body composition meaningfully in healthy adults Long-term safety Short-term tolerability appears acceptable in studied settings4 Multi-year safety, especially any oncologic signal from raised IGF-1 Several of these gaps deserve emphasis because they are routinely papered over. The healthy-adult body-composition question is largely unstudied for Sermorelin itself; the visceral-fat data belong to tesamorelin in a specific disease population, and importing them is precisely the analog-substitution error.10 The long-term safety question is not hypothetical hand-wringing: IGF-1 is a mitogen, epidemiology links higher IGF-1 to certain cancer risks, and any intervention that chronically raises IGF-1 in older adults carries a theoretical oncologic concern that short trials cannot exclude. That the Baker trial kept IGF-1 “within the physiological range” is reassuring for that protocol but does not settle the matter for uncontrolled, indefinite off-label use.5 And the durability question follows directly from the pharmacology: a compound cleared in minutes, dosed to nudge nightly pulses, has no established multi-year outcome data in the wellness populations now using it. It is worth being blunt about the shape of the literature itself, because the type of evidence matters as much as its quantity. The frequently cited case for adult Sermorelin rests substantially on a two-page 2006 commentary framing it as “a better approach” to adult-onset GH insufficiency — a thoughtful argument from mechanism and clinical reasoning, but explicitly a hypothesis-generating perspective piece, not a randomized controlled trial reporting hard endpoints.4 There is, to date, no large, modern, placebo-controlled outcome trial of Sermorelin itself in healthy or aging adults that measures function, body composition, cognition, or safety over years and clears contemporary methodological standards. What exists instead is a scaffold assembled from three weaker supports: the robust but pediatric-diagnostic dataset for which the drug was approved,3 the well-run trials of other GHRH analogs such as tesamorelin,510 and the biologically reasonable but unproven inference that the same axis stimulation will translate into benefit. Recognizing that structure is not cynicism; it is simply reading the evidence at the level of rigor it actually occupies rather than the level its marketing implies. The methodological bottom line is that Sermorelin’s evidence architecture was built to answer a pediatric-diagnostic question and answered it well. It was not built to answer the adult anti-aging, body-composition, or cognition questions now asked of it, and those answers cannot be manufactured by borrowing from tesamorelin or from mechanism. For a grounded look at what the primary literature does and does not say about the compound’s core action, the site’s overview of what research says about Sermorelin’s role in stimulating natural growth hormone stays close to the demonstrated pharmacology.

Source: dosagepeptide.com ↗

Human SNAP-8 Research Formulations

Human evidence is topical or device-assisted. Conventional cream data come from ingredient-developer testing. Peer-reviewed studies used multi-active serums or dissolving microneedle patches, so their outcomes cannot be assigned to SNAP-8 alone. Lipotec developer panel[6] Cream with 10% of a nominal 0.05% SNAP-8 solution, equal to about 0.005% active peptide Twice daily around the eye area for 28 days 17 women; silicone replicas and profilometry; about 35% mean and 63% maximum wrinkle-depth reduction reported Manufacturer-reported, not an independent peer-reviewed trial Shin et al. (2024)[1] 350 micrometer dissolving patch with 0.03% SNAP-8, 5% AA2G, 4% cyclic LPA, and 90% HA Overnight nightly through day 14, then every third day through day 28 24 enrolled and 21 completed a split-face active-versus-placebo comparison Combination device; SNAP-8’s independent contribution cannot be isolated Avcil et al. (2020)[2] HA microneedle patch with SNAP-8, other peptides, adenosine, and seaweed extracts 12-week study Fine lines, hydration, dermal density, thickness, and tolerability measures Multi-active product; SNAP-8 concentration was not disclosed in the abstract Draelos et al. (2016)[3] Multi-peptide serum containing SNAP-8 within a supporting skincare regimen Morning and evening for 12 weeks after a 2-week washout 29 women; investigator grading and participant questionnaires Open label, no control, multiple peptides and supporting products Moy et al. (2023)[4] Proprietary multi-peptide facial serum containing acetyl octapeptide-3 Twice daily for 12 weeks 31 women completed dermatologist grading, imaging, hydration, and questionnaires Uncontrolled, multi-ingredient, and company funded

Source: peptidedosages.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

How-to reference

How to convert mcg to mg (and back)

Because the factor is exactly 1000, every conversion is a decimal-point move of three places — no calculator strictly required once you see the pattern: mcg → mg: divide by 1000, i.e. move the decimal point three places to the left. 500 mcg → 0.5 mg; 100 mcg → 0.1 mg; 1500 mcg → 1.5 mg. mg → mcg: multiply by 1000, i.e. move the decimal point three places to the right. 0.5 mg → 500 mcg; 2 mg → 2000 mcg; 1.25 mg → 1250 mcg. The tool above does the same move for you and trims trailing zeros, so you can paste in any value — whole or fractional — and read the exact counterpart.

Source: dosagepeptide.com ↗
Dosage reference

PNC-27 Dosage, Reconstitution & Mixing Trends

Explore PNC-27 dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions. PNC-27 is a synthetic peptide combining a p53-derived sequence with a membrane-penetrating leader domain, studied in preclinical cancer research for its proposed ability to selectively disrupt the membranes of cancer cells that express HDM-2 on their surface while sparing normal cells. This data shows the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when reconstituting PNC-27. 4 PNC-27 reconstitution calculations have been logged by the WPA community. The most common dose entered is 200mcg (2 calculations). The most common bacteriostatic water volume is 3mL. The most popular vial size is 10mg (3 sessions). World Peptide Association aggregates anonymized peptide calculator data to show real-world dosing trends, reconstitution volumes, and vial size preferences across the research peptide community. All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.

Source: worldpeptideassociation.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →